FIELD: medicine, experimental cardiology.
SUBSTANCE: one should intragastrically introduce claritromycin at the dosage of 30 mg/kg 15 min before coronary occlusion in the course of experimental coronary occlusion myocardial infarction. The innovation provides significant decrease of the necrosis area due to cardioprotector action of claritromycin.
EFFECT: higher efficiency.
1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR RESTRICTING THE NECROSIS AREA WITH ROXYTROMYCIN WHILE MODELING CORONARY OCCLUSION MYOCARDIAL INFARCTION IN ANIMALS | 2006 |
|
RU2318506C1 |
| METHOD FOR RESTRICTING NECROSIS AREA AT MODELING CORONAROOCCLUSION MYOCARDIAL INFARCTION IN ANIMALS AT DECREASED ANTIOXIDANT BACKGROUND | 2002 |
|
RU2226101C2 |
| MIDECAMYCIN-BASED CORRECTION MODE OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | 2007 |
|
RU2353370C1 |
| JOSAMYCIN THERAPY FOR ENDOTHELIUM DYSFUNCTION CORRECTION ASSOCIATED WITH L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | 2007 |
|
RU2353369C1 |
| METHOD FOR INCREASING SURVIVAL RATE OF ISOLATED SKIN PEDICLE FLAP IN ANIMALS HAVING REDUCED ANTIOXIDATION BACKGROUND | 2002 |
|
RU2283116C2 |
| METHOD OF CORRECTING ENDOTHELIAL DYSFUNCTION WITH AZITHROMYCIN IN MODELING OF CHRONIC GRAM-POSITIVE SEPSIS | 2009 |
|
RU2400826C1 |
| METHOD FOR AZITHROMYCIN-BASED ENDOTHELIAL DYSFUNCTION CORRECTION IN EXPERIMENTAL REACTIVE VASCULITIS | 2009 |
|
RU2402333C1 |
| METHOD FOR CORRECTION OF PLACENTAL MICROCIRCULATION DISORDER WITH SUBSTANCE OF 3-HYDROXY-2-ETHYL-6-METHYLPYRIDINIUM NICOTINATE IN ADMA-LIKE MODEL OF PREECLAMPSIA | 2020 |
|
RU2735766C1 |
| METHOD FOR CORRECTING ENDOTHELIAL DYSFUNCTION WITH SUBSTANCE OF 3-HYDROXY-2-ETHYL-6-METHYLPYRIDINIUM NICOTINATE IN AN ADMA-LIKE MODEL OF PREECLAMPSIA | 2020 |
|
RU2735903C1 |
| METHOD OF CORRECTING MORPHOLOGICAL CHANGES IN PLACENTA WITH SUBSTANCE OF 3-HYDROXY-2-ETHYL-6-METHYLPYRIDINIUM NICOTINATE IN ADMA-LIKE MODEL OF PREECLAMPSIA | 2020 |
|
RU2735765C1 |
